XR 11612
Alternative Names: MLN 612; XR11612Latest Information Update: 08 Aug 2007
At a glance
- Originator Xenova Group
- Class Antineoplastics; Phenazines
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Apr 2006 No development reported - Preclinical for Cancer in United Kingdom (PO)
- 07 Jan 2002 XR 11612 licensed to Millennium Pharmaceuticals in North America
- 29 Nov 2001 Preclinical development for Cancer in United Kingdom (IV)